Issue 1 of the ESC Bench to Bedside series explores the evolving role of non-steroidal mineralocorticoid receptor antagonists (MRAs) in heart failure management. Across three focused webinars, this edition provides a structured journey from foundational science through clinical trial evidence to practical applications in patient care.

The first session delves into the basic science, highlighting how non-steroidal MRAs differ from their steroidal counterparts in terms of mechanism of action and physiological impact. The second webinar focuses on key findings from major randomised controlled trials—FIDELITY, FIDELIO-DKD, and FINEARTS-HF—clarifying which patient groups stand to benefit most. The final session translates this evidence into practice, offering guidance on patient selection, dosing, monitoring, and safety considerations.

By addressing knowledge gaps from molecular biology to bedside decision-making, this issue equips cardiology professionals with the insights needed to responsibly and effectively integrate non-steroidal MRAs into heart failure therapy.